Previous 10 | Next 10 |
SAN DIEGO and VANCOUVER, British Columbia , Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of ...
Sophiris Bio (NASDAQ: SPHS ): Q2 GAAP EPS of -$0.07 beats by $0.04 . More news on: Sophiris Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO and VANCOUVER, British Columbia , Aug. 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment...
SAN DIEGO and VANCOUVER, British Columbia , June 19, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tre...
Sophiris Bio (NASDAQ: SPHS ): Q1 GAAP EPS of -$0.08 beats by $0.02 . More news on: Sophiris Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO and VANCOUVER, British Columbia , May 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tr...
The following slide deck was published by Sophiris Bio, Inc. in conjunction with this Read more ...
SAN DIEGO and VANCOUVER, British Columbia , April 2, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for th...
Sophiris Bio (NASDAQ: SPHS ): Q4 GAAP EPS of $0.18. More news on: Sophiris Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO and VANCOUVER, British Columbia , March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the trea...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO and VANCOUVER, British Columbia , May 18, 2020 /PRNewswire/ -- Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Compa...
SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tre...
SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseas...